公开(公告)号：WO1997035588A1

公开(公告)日：1997-10-02

申请号：PCT/US1997004841

申请日：1997-03-25

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  WELLS, Alan ,  CHEN, Philip ,  TURNER, Timothy

IPC: A61K31/66

CPC classification number: A61K31/685 ,  A61K31/15 ,  A61K31/27 ,  A61K31/58

Abstract: The present invention provides a method of inhibiting tumor progression in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Also provided is a method of inhibiting metastasis in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Further provided are pharmaceutical compositions, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis and a pharmaceutically acceptable carrier and a pharmaceutical composition, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis, an antineoplastic agent and a pharmaceutically acceptable carrier.

Abstract translation: 本发明提供抑制需要这种治疗的个体中肿瘤进展的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了在需要这种治疗的个体中抑制转移的方法，包括向所述个体施用药理学有效剂量的磷脂酶C抑制剂的步骤。 还提供了包含肿瘤侵袭和转移的磷脂酶C抑制剂和药学上可接受的载体和药物组合物的药物组合物，其包含肿瘤侵袭和转移的磷脂酶C抑制剂，抗肿瘤剂和药学上可接受的载体。

公开(公告)号：WO1997034611A1

公开(公告)日：1997-09-25

申请号：PCT/US1997003464

申请日：1997-03-21

Applicant: UAB RESEARCH FOUNDATION ,  BEDWELL, David, M.

Inventor： UAB RESEARCH FOUNDATION

IPC: A61K31/70

CPC classification number: A61K31/7036 ,  A61K31/7048 ,  Y10S514/866

Abstract: The present invention provides a method of stimulating expression of a functional full-length cystic fibrosis transmembrane conductance regulator protein in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside. Also provided is a method of treating cystic fibrosis in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of an aminoglycoside. Further provided is a method of screening for a drug useful in the treatment of an individual having cystic fibrosis, comprising the step of determining said drug's ability to suppress premature stop mutations in a model of cystic fibrosis and a method of pharmacologically suppressing premature stop mutations in an individual having such mutations, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.

Abstract translation: 本发明提供了在需要这种治疗的个体中刺激功能性全长囊性纤维化跨膜传导调节蛋白的表达的方法，其包括向所述个体施用药理学有效剂量的氨基糖苷类的步骤。 还提供了在需要这种治疗的个体中治疗囊性纤维化的方法，包括向所述个体施用治疗有效剂量的氨基糖苷的步骤。 进一步提供筛选用于治疗患有囊性纤维化的个体的药物的方法，包括确定所述药物在囊性纤维化模型中抑制过早停止突变的能力的步骤，以及药理学上抑制过早停止突变的方法 具有这种突变的个体，包括向所述个体施用药理学有效剂量的氨基糖苷的步骤。

公开(公告)号：WO1996029441A3

公开(公告)日：1996-09-26

申请号：PCT/US1996003391

申请日：1996-03-13

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  VOHRA, Yogesh, K. ,  MCCAULEY, Thomas, S.

IPC: C30B29/04

公开(公告)号：WO1996022370A1

公开(公告)日：1996-07-25

申请号：PCT/US1996000606

申请日：1996-01-19

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  MOUNTZ, John, D. ,  LIU, Changdan ,  CHENG, Jianhua ,  KOOPMAN, William, J. ,  ZHOU, Tong

IPC: C12N15/12

CPC classification number: A01K67/0275 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/715 ,  C12N15/67 ,  C12N2799/022 ,  C12N2799/027

Abstract: Disclosed is a 5' flanking sequence of the human fas gene containing a promoter region. This sequence also contains at least three transcription initiation sites, as well as consensus sequences for AP-1, GF-1, NY-Y, CP-2, EB20, and c-myb. Also disclosed are methods of altering senescence of the immune system by modifying Fas activity in cells to increase or decrease apoptosis. Fas expression and function on T cells from old (22-26-month-old) mice is also compared to young (2-month-old) mice and old CD2-fas transgenic mice. Fas expression and ligand-induced apoptosis was decreased on T cells from old mice compared to young mice. In 26-month-old CD2-fas transgenic mice, Fas and CD44 expression, Fas-induced apoptosis, T cell proliferation and cytokine production were comparable to that of the young mice. These results suggest that T cell senescence with age is associated with defective apoptosis and that the CD2-fas transgene allows the maintenance of Fas apoptosis function and T cell function in aged mice comparable to that of young mice.

Abstract translation: 披露了含有启动子区的人fas基因的5'侧翼序列。 该序列还含有至少三个转录起始位点，以及AP-1，GF-1，NY-Y，CP-2，EB20和c-myb的共有序列。 还公开了通过改变细胞中的Fas活性来增加或减少凋亡来改变免疫系统衰老的方法。 将老年（22-26个月大）小鼠的T细胞的Fas表达和功能与年轻（2月龄）的小鼠和老的CD2-fas转基因小鼠进行比较。 与老年小鼠相比，来自老鼠的T细胞的Fas表达和配体诱导的凋亡降低。 在26个月大的CD2-fas转基因小鼠中，Fas和CD44表达，Fas诱导的凋亡，T细胞增殖和细胞因子产生与年轻小鼠相当。 这些结果表明，随着年龄的增长，T细胞衰老与细胞凋亡有关，CD2-fas转基因能够维持老年小鼠Fas细胞凋亡功能和T细胞功能，与年轻小鼠相当。

公开(公告)号：WO1996017936A2

公开(公告)日：1996-06-13

申请号：PCT/US1995016108

申请日：1995-12-11

Applicant: UNIVERSITY OF FLORIDA ,  UAB RESEARCH FOUNDATION

Inventor： UNIVERSITY OF FLORIDA ,  UAB RESEARCH FOUNDATION ,  PROGULSKE-FOX, Ann ,  TUMWASORN, Somying ,  LEPINE, Guylaine ,  HAN, Naiming ,  LANTZ, Marilyn ,  PATTI, Joseph, M.

IPC: C12N15/31

CPC classification number: C12N9/52 ,  A61K38/00 ,  A61K39/00 ,  C07K14/195

Abstract: DNA fragments from Porphyromonas gingivalis which express hemagglutinin/proteases that elicit anti-P. gingivalis immunologic responses are described. Microorganisms, genetically modified to express P. gingivalis antigens, are provided. Also disclosed are probes, vaccines, and monoclonal antibodies for the detection and prevention of periodontal disease.

Abstract translation: 来自牙龈卟啉单胞菌的DNA片段，其表达引起抗P的血凝素/蛋白酶。 描述牙龈免疫反应。 提供转基因表达牙龈卟啉菌抗原的微生物。 还公开了用于检测和预防牙周病的探针，疫苗和单克隆抗体。

公开(公告)号：WO1992019183A2

公开(公告)日：1992-11-12

申请号：PCT/US1992002691

申请日：1992-04-03

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  URRY, Dan, W.

IPC: A61F02/06

CPC classification number: A61L27/14 ,  A61F2/28 ,  A61F2/30756 ,  A61K9/2045 ,  A61L27/50

Abstract: A composition that expands against an exerted pressure, which comprises a polymeric material having an inverse temperature transition in the range of liquid water, wherein at least a fraction of the monomers in the polymer contain a hydrophobic group that is present in an amount sufficient to provide PdV/dS for the polymer of at least 0.2 DEG K. The composition can be used in a variety of different application to produce mechanical work or cause chemical changes in a sealed environment by varying the pressure on the composition, with the degree of mechanical or chemical change being controlled by selection of the number, hydrophobicity, and size of the hydrophobic group and the presence or absence of reactive functional groups in the polymer.

Abstract translation: 一种在施加于其上的压力作用下膨胀的组合物，该组合物包含一种聚合物材料，其逆向热转变接近液态水的聚合物材料，其中聚合物中存在的至少一部分单体 含有足以使聚合物的压力 - 三角 - 体积/三角洲/熵比为至少0.2°K的比例的疏水基团。 该组合物可用于大量不同的应用中，以获得机械功或在密封环境中产生化学改性，通过改变组合物的压力，机械或化学改性的程度由 数量的选择，疏水性的程度，疏水性基团的大小以及聚合物中反应性官能团的存在或不存在。

公开(公告)号：WO1992008482A1

公开(公告)日：1992-05-29

申请号：PCT/US1991007894

申请日：1991-10-24

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  BECKMAN, Joseph, S. ,  SMITH, Craig, D. ,  ISCHIROPOULOS, Haralambos

IPC: A61K37/48

CPC classification number: C12N9/0089 ,  A61K38/00

Abstract: Compositions for reducing oxidative injury to an animal that includes a modified superoxide dismutase, wherein the modification comprises substituting a first amino acid residue located within 3-12 ANGSTROM of the active site of the superoxide dismutase with a second amino acid residue capable of reacting with a highly reactive nitrating species, such as nitronium ion, formed from the reaction of peroxynitrite and superoxide dismutase.

Abstract translation: 用于减少对包含修饰的超氧化物歧化酶的动物的氧化损伤的组合物，其中所述修饰包括用位于所述超氧化物歧化酶活性位点的3-12个神经元内的第一个氨基酸残基与能够与 高反应硝化物质，如硝酸根离子，由过氧亚硝酸盐和超氧化物歧化酶的反应形成。

公开(公告)号：WO1998011938A1

公开(公告)日：1998-03-26

申请号：PCT/US1997016082

申请日：1997-09-11

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  WALCOTT, Gregory, P. ,  IDEKER, Raymond, E. ,  WARREN, Jay, Alan

IPC: A61N01/00

CPC classification number: A61B18/1492 ,  A61B2018/0075 ,  A61B2018/00869 ,  A61B2018/124 ,  A61B2018/1467

Abstract: An electrode catheter is disclosed for creating a linear lesion in heart tissue of a heart chamber in order to correct cardiac arrhythmia. The catheter is elongated in dimension such that, upon insertion of the catheter in the patient, the catheter substantially continuously contacts either the endocardial or epicardial heart tissue. The catheter (12) includes a plurality of electrodes (14) and the electrodes are positioned at spaced intervals along the catheter (12). The electrodes are then sequentially energized with a radio frequency (20) in conjunction with a back plate (22) attached to the patient such that the electrodes form a continuous lesion conforming in shape to the shape of the catheter on the heart tissue. This lesion, furthermore, is of sufficient depth such that the lesion interrupts electrical nodal conduction across the lesion.

Abstract translation: 公开了用于在心室的心脏组织中产生线性损伤以矫正心律失常的电极导管。 导管的尺寸是细长的，使得当将导管插入患者体内时，导管基本上连续接触心内膜或心外膜心脏组织。 导管（12）包括多个电极（14），并且电极沿着导管（12）间隔定位。 然后使用射频（20）与连接到患者的背板（22）连续激活电极，使得电极形成与心脏组织上的导管形状一致的连续病变。 此外，这种病变具有足够的深度，使得病变中断穿过病变的电节点传导。

公开(公告)号：WO1997008788A2

公开(公告)日：1997-03-06

申请号：PCT/US1996014182

申请日：1996-08-14

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  VAUGHAN, John, Thomas

IPC: H01S00/00

CPC classification number: G01R33/345 ,  G01R33/34007 ,  G01R33/34046 ,  G01R33/34092

Abstract: A cavity resonator is disclosed for use in nuclear magnetic resonance (NMR) systems. The resonator has a housing defining a cavity having a selected length and cross-sectional shape. A layer of electrically conductive material is provided around at least a portion of the housing enclosing a dielectric material (air, gasses, teflon, etc.) and the cavity is energized at a Larmor radio frequency useful for NMR systems. The cavity, i.e. a volume enclosed by conductive walls, furthermore, is dimensioned to resonate at the selected radio frequency to thereby generate an alternating magnetic field through the cavity. An opening in the housing is adapted to be placed adjacent an object to be analyzed.

Abstract translation: 公开了用于核磁共振（NMR）系统的空腔谐振器。 谐振器具有限定具有选定长度和横截面形状的空腔的壳体。 围绕包围介电材料（空气，气体，聚四氟乙烯等）的壳体的至少一部分设置导电材料层，并且该空腔以对于NMR系统有用的拉莫尔射频进行激励。 此外，空腔，即由导电壁包围的体积的尺寸被设计成在所选择的射频频率下谐振，从而通过空腔产生交变磁场。 壳体中的开口适于放置在待分析对象附近。

公开(公告)号：WO1995000151A1

公开(公告)日：1995-01-05

申请号：PCT/US1994007123

申请日：1994-06-23

Applicant: UAB RESEARCH FOUNDATION

Inventor： UAB RESEARCH FOUNDATION ,  MEEZAN, Elias ,  PILLION, Dennis, J.

IPC: A61K31/70

CPC classification number: A61K9/0043 ,  A61K9/0048 ,  A61K38/26 ,  A61K38/28 ,  A61K47/26 ,  Y10S514/912

Abstract: The present invention relates to a method of increasing the absorption of a compound via the ocular, nasal, nasolacrimal or inhalation route into the circulatory system of a patient. In particular, a method comprising administering with the compound an absorption enhancer comprising a nontoxic, nonionic alkyl glycoside is provided. Additionally provided are methods of raising or lowering the blood glucose level by administering glucagon or insulin, respectively, with such absorption enhancers. Finally, compositions for raising or lowering the blood glucose level are provided.

Abstract translation: 本发明涉及通过眼，鼻，鼻泪或吸入途径将化合物吸收到患者的循环系统中的方法。 特别地，提供了一种包括向化合物施用包含无毒非离子烷基糖苷的吸收增强剂的方法。 另外提供了通过分别用这种吸收促进剂施用胰高血糖素或胰岛素来提高或降低血糖水平的方法。 最后，提供用于升高或降低血糖水平的组合物。